IP Library Granted Patent US 7,473,678
Granted Patent B2
US 7,473,678 · App. 11/159,533 · Granted Jan 6, 2009

Platelet-derived growth factor compositions and methods of use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,473,678
App. No.
11/159,533
Granted
Jan 6, 2009
Kind
B2
Abstract

A method for promoting growth of bone, periodontium, ligament, or cartilage in a mammal by applying to the bone, periodontium, ligament, or cartilage a composition comprising platelet-derived growth factor at a concentration in the range of about 0.1 mg/mL to about 1.0 mg/mL in a pharmaceutically acceptable liquid carrier and a pharmaceutically-acceptable solid carrier.

Claims (45)

1. An implant material consisting of a porous calcium phosphate having incorporated therein a liquid consisting of platelet derived growth factor (PDGF) at a concentration in a range of about 0.1 mg/mL to about 1.0 mg/mL in a buffer, wherein the calcium phosphate has interconnected pores, a porosity greater than 40%, and consists of particles in a range of about 100 microns to about 5000 microns in size.

2. The implant material of claim 1 wherein the PDGF is recombinant PDGF.

3. The implant material of claim 1 wherein the PDGF is recombinant PDGF-BB.

4. The implant material of claim 1 wherein the liquid consists of PDGF at a concentration of about 0.3 mg/mL in a buffer.

5. The implant material of claim 1 wherein the liquid consists of PDGF at a concentration in a range of about 0.25 mg/mL to about 0.5 mg/mL in a buffer.

6. The implant material of claim 1 wherein the calcium phosphate is tricalcium phosphate.

7. The implant material of claim 1 wherein the calcium phosphate consists of particles in a range of about 100 microns to about 3000 microns in size.

8. The implant material of claim 1 wherein the calcium phosphate consists of particles in a range of about 250 microns to about 1000 microns in size.

9. The implant material of claim 1 wherein the implant material is resorbable such that at least 80% of the calcium phosphate is resorbed within one year of being implanted.

10. The implant material of claim 1 wherein the incorporated liquid is adsorbed or absorbed to the calcium phosphate.

11. An implant material consisting of a calcium phosphate having incorporated therein a liquid consisting of platelet derived growth factor (PDGF) at a concentration in a range of about 0.1 mg/mL to about 1.0 mg/mL in a buffer, wherein the implant material is a composition having a porosity that facilitates cell migration into the composition and the calcium phosphate has interconnected pores and consists of particles in a range of about 100 microns to about 5000 microns in size.

12. The implant material of claim 11 wherein said porosity is macroporosity.

13. The implant material of claim 11 wherein said porosity consists of porous calcium phosphate particles having a porosity greater than 40%.

14. The implant material of claim 11 wherein the PDGF is recombinant human (rh) PDGF-BB.

15. The implant material of claim 11 wherein the calcium phosphate is tricalcium phosphate.

16. The implant material of claim 11 wherein the calcium phosphate consists of particles in a range of about 100 microns to about 3000 microns in size.

17. The implant material of claim 11 wherein the calcium phosphate consists of particles in a range of about 250 microns to about 2000 microns in size.

18. The implant material of claim 11 wherein the calcium phosphate consists of particles in a range of about 250 microns to about 1000 microns in size.

19. The implant material of claim 11 wherein the liquid consists of PDGF at a concentration of about 0.3 mg/mL in a buffer.

20. The implant material of claim 11 wherein the liquid consists of PDGF at a concentration in a range of about 0.25 mg/mL to about 0.5 mg/mL in a buffer.

21. The implant material of claim 11 wherein the liquid consists of PDGF at a concentration in a range of about 0.2 mg/mL to about 0.75 mg/mL in a buffer.

22. The implant material of claim 11 wherein the implant material is resorbable such that at least 80% of the calcium phosphate is resorbed within one year of being implanted.

23. An implant material consisting of collagen and a porous calcium phosphate having incorporated therein a liquid consisting of platelet derived growth factor (PDGF) at a concentration in a range of about 0.1 mg/mL to about 1.0 mg/mL in a buffer, wherein the calcium phosphate has interconnected pores, a porosity greater than 40%, and consists of particles in a range of about 100 microns to about 5000 microns in size.

24. The implant material of claim 23 wherein the PDGF is recombinant human (rh) PDGF-BB and the calcium phosphate is tricalcium phosphate.

25. The implant material of claim 23 wherein the calcium phosphate consists of particles in a range of about 100 microns to about 3000 microns in size.

26. The implant material of claim 23 wherein the calcium phosphate consists of particles in a range of about 250 microns to about 1000 microns in size.

27. The implant material of claim 23 wherein the liquid consists of PDGF at a concentration of about 0.3 mg/mL in a buffer.

28. The implant material of claim 23 wherein the implant material is resorbable such that at least 80% of the calcium phosphate is resorbed within one year of being implanted.

29. An implant material consisting of collagen and a calcium phosphate having incorporated therein a liquid consisting of platelet derived growth factor (PDGF) at a concentration in a range of about 0.1 mg/mL to about 1.0 mg/mL in a buffer, wherein the implant material is a composition having a porosity that facilitates cell migration into the composition and the calcium phosphate has interconnected pores and consists of particles in a range of about 100 microns to about 5000 microns in size.

30. The implant material of claim 29 wherein said porosity is macroporosity.

31. The implant material of claim 29 wherein said porosity consists of porous calcium phosphate particles having a porosity greater than 40%.

32. The implant material of claim 29 wherein the PDGF is recombinant human (rh) PDGF-BB and the calcium phosphate is tricalcium phosphate.

33. The implant material of claim 29 wherein the calcium phosphate consists of particles in a range of about 100 microns to about 3000 microns in size.

34. The implant material of claim 29 wherein the calcium phosphate consists of particles in a range of about 250 microns to about 1000 microns in size.

35. The implant material of claim 29 wherein the liquid consists of PDGF at a concentration of about 0.3 mg/mL in a buffer.

36. An implant material consisting of a calcium phosphate having incorporated therein a liquid consisting of platelet derived growth factor (PDGF) at a concentration in a range of about 0.1 mg/mL to about 1.0 mg/mL in a buffer, wherein the calcium phosphate has interconnected pores and consists of particles in a range of about 100 microns to about 5000 microns in size, and wherein the calcium phosphate is capable of absorbing an amount of the liquid consisting of PDGF that is equal to at least about 25% of the calcium phosphate's own weight.

37. The implant material of claim 36 , wherein the calcium phosphate is capable of absorbing an amount of the liquid consisting of PDGF that is equal to at least about 50% of the calcium phosphate's own weight.

38. The implant material of claim 37 , wherein the calcium phosphate is capable of absorbing an amount of the liquid consisting of PDGF that is equal to at least about 200% of the calcium phosphate's own weight.

39. The implant material of claim 38 , wherein the calcium phosphate is capable of absorbing an amount of the liquid consisting of PDGF that is equal to at least about 300% of the calcium phosphate's own weight.

40. An implant material consisting of collagen and a calcium phosphate having incorporated therein a liquid consisting of platelet derived growth factor (PDGF) at a concentration in a range of about 0.1 mg/mL to about 1.0 mg/mL in a buffer, wherein the calcium phosphate has interconnected pores and consists of particles in a range of about 100 microns to about 5000 microns in size, and wherein the calcium phosphate and collagen are capable of absorbing an amount of the liquid consisting of PDGF that is equal to at least about 25% of the weight of the calcium phosphate and collagen.

41. The implant material of claim 40 , wherein the calcium phosphate and collagen are capable of absorbing an amount of the liquid consisting of PDGF that is equal to at least about 50% of the weight of the calcium phosphate and collagen.

42. The implant material of claim 41 , wherein the calcium phosphate and collagen are capable of absorbing an amount of the liquid consisting of PDGF that is equal to at least about 200% of the weight of the calcium phosphate and collagen.

43. The implant material of claim 42 , wherein the calcium phosphate and collagen are capable of absorbing an amount of the liquid consisting of PDGF that is equal to at least about 300% of the weight of the calcium phosphate and collagen.

44. An implant material consisting of a calcium phosphate having incorporated therein a liquid consisting of platelet derived growth factor (PDGF) at a concentration of about 0.3 mg/mL in a buffer, wherein the calcium phosphate has interconnected pores and consists of particles in a range of about 100 microns to about 5000 microns in size, and wherein the calcium phosphate is capable of absorbing an amount of the liquid consisting of PDGF that is equal to at least about 25% of the calcium phosphate's own weight.

45. An implant material consisting of collagen and a calcium phosphate having incorporated therein a liquid consisting of platelet derived growth factor (PDGF) at a concentration of about 0.3 mg/mL in a buffer, wherein the calcium phosphate has interconnected pores and consists of particles in a range of about 100 microns to about 5000 microns in size, and wherein the calcium phosphate and collagen are capable of absorbing an amount of the liquid consisting of PDGF that is equal to at least about 25% of the weight of the calcium phosphate and collagen.

Assignments (5)
NUNC PRO TUNC ASSIGNMENT Recorded Apr 15, 2025
From: BIOMIMETIC THERAPEUTICS, LLC
To: STRYKER CORPORATION
Reel/Frame 070841/0053 →
RELEASE OF SECURITY INTEREST Recorded Nov 19, 2020
From: MIDCAP FUNDING IV TRUST
To: WRIGHT MEDICAL GROUP N.V.; WRIGHT MEDICAL GROUP, INC.; BIOMIMETIC THERAPEUTICS CANADA, INC.; BIOMIMETIC THERAPEUTICS, LLC; BIOMIMETIC THERAPEUTICS USA, INC.; INBONE TECHNOLOGIES, INC.; ORTHOHELIX SURGICAL DESIGNS, INC.; ORTHOPRO, L.L.C.; SOLANA SURGICAL, LLC; TORNIER US HOLDINGS, INC.; TORNIER, INC.; TROOPER HOLDINGS INC.; WHITE BOX ORTHOPEDICS, LLC; WRIGHT MEDICAL CAPITAL, INC.; WRIGHT MEDICAL TECHNOLOGY, INC.; WRIGHT MEDICAL GROUP INTELLECTUAL PROPERTY, INC.
Reel/Frame 054480/0001 →
SECURITY INTEREST Recorded Jan 5, 2017
From: BIOMIMETIC THERAPEUTICS, LLC
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 040853/0901 →
MERGER Recorded Jul 19, 2013
From: BIOMIMETIC THERAPEUTICS, INC.
To: BIOMIMETIC THERAPEUTICS, LLC
Reel/Frame 030840/0514 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2005
From: LYNCH, SAMUEL E.
To: BIOMIMETIC THERAPEUTICS, INC.
Reel/Frame 017017/0539 →